Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Coherus BioSciences revenue
Coherus BioSciences's revenue is $267.0 million.
What is Coherus BioSciences's revenue?
- Coherus BioSciences's revenue growth from 2013 to 2024 is 9,604.11%.
- Coherus BioSciences has 232 employees, and the revenue per employee ratio is $1,150,689.
- Coherus BioSciences's peak quarterly revenue was $162.8M in 2016(q3).
- Coherus BioSciences peak revenue was $475.8M in 2020.
- Coherus BioSciences annual revenue for 2023 was 257.2M, 21.89% growth from 2022.
- Coherus BioSciences annual revenue for 2024 was 267.0M, 3.78% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Coherus BioSciences historical revenue
Coherus BioSciences's peak revenue was $475.8M in 2020. The peak quarterly revenue was $162.8M in 2016(q3).
Coherus BioSciences's revenue increased from $2.8m in 2013 to $267.0M currently. That's a 9,604.11% change in annual revenue.
Coherus BioSciences annual revenue
Coherus BioSciences annual revenue over time
| Fiscal year / year | Coherus BioSciences revenue |
|---|---|
| 2013 | $2.8M |
| 2014 | $31.1M |
| 2015 | $30.0M |
| 2016 | $190.1M |
| 2017 | $1.6M |
| 2019 | $356.1M |
| 2020 | $475.8M |
| 2021 | $326.6M |
| 2022 | $211.0M |
| 2023 | $257.2M |
| 2024 | $267.0M |
How accurately did Coherus BioSciences' revenue projections match actual performance?
Coherus BioSciences annual growth
Coherus BioSciences saw the greatest revenue growth in 2019, when revenue increased by 22,783.74%.
Coherus BioSciences had the lowest revenue growth in 2017, when revenue changed by -99.18%.
Coherus BioSciences annual growth rate over time
| Year | Coherus BioSciences growth |
|---|---|
| 2014 | 1031%↑ |
| 2015 | -3%↓ |
| 2016 | 533%↑ |
| 2017 | -99%↓ |
| 2019 | 22784%↑ |
| 2020 | 34%↑ |
| 2021 | -31%↓ |
| 2022 | -35%↓ |
| 2023 | 22%↑ |
| 2024 | 4%↑ |
Coherus BioSciences quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Coherus BioSciences quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | - | $16.1M | $6.5M |
| 2015 | $5.8M | $6.9M | $7.2M | $10.2M |
| 2016 | $12.4M | $14.1M | $162.8M | $844,000 |
| 2017 | $161,000 | $1.4M | - | - |
| 2019 | $37.1M | $83.4M | $111.7M | $123.9M |
| 2020 | $116.2M | $135.7M | $113.6M | $110.4M |
| 2021 | $83.0M | $87.6M | $82.5M | $73.4M |
| 2022 | $60.1M | $60.2M | $45.4M | $45.4M |
| 2023 | $32.4M | $58.7M | $74.6M | $91.5M |
| 2024 | $77.1M | $65.0M | $70.8M | $54.1M |
Coherus BioSciences jobs nearby
Do you work at Coherus BioSciences?
Did Coherus BioSciences meet its revenue projections?
Coherus BioSciences financial information
| CEO | Dennis M. Lanfear |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 232 |
| Date Founded | 2010 |
| Headquarters | Redwood City, California |
| Number of Locations | 2 |
| Revenue | $267.0M |
| Net Income | -$291,754,000 |
| Gross Proft | $149.4M (2024) |
| PE Ratio | 24.68 |
| Tax Rate | -0.0% |
| Market Capitalization | $703.4M |
| Total Assets | $480,847,000 |
| Ticker | CHRS |
Coherus BioSciences jobs you might like
Coherus BioSciences financing
Coherus BioSciences received early financing of $1.5M on 2011-03-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $1.5M | 03/2011 |
| Series B | $61.5M | 01/2012 |
| Debt Financing | $28M | 07/2013 |
| Series C | $54.7M | 05/2014 |
| Post Ipo Equity | $100M | 02/2016 |
| Post Ipo Equity | $125M | 02/2017 |
| Post Ipo Equity | $6.8M | 12/2017 |
| Post Ipo Debt | $75M | 01/2019 |
| Post Ipo Equity | $50M | 02/2021 |
| Post Ipo Debt | $100M | 01/2022 |
Coherus BioSciences investors
| Investors | Security type |
|---|---|
| Helix Ventures | Series A |
| Medpace | Series A |
| Cook Pharmica LLC | Series B |
| Helix Ventures | Series B |
| Daiichi Sankyo Inc | Series B |
| Medpace | Series B |
| Lilly Ventures | Series B |
| Helix Ventures | Debt Financing |
| Helix Ventures | Series C |
| Eight Roads Ventures | Series C |
| Viva Capital Advisors | Series C |
| KMG Capital Partners | Series C |
| Venrock | Series C |
| Lilly Ventures | Series C |
| Vivo Capital | Series C |
| SOFINNOVA INVESTMENTS INC | Series C |
| F Prime Capital | Series C |
| KKR & Co. Inc. | Series C |
| RA Capital Management | Series C |
| Rock Springs Capital | Series C |
| HealthCare Royalty Partners | Post Ipo Debt |
| Shanghai Junshi Biosciences Co Ltd | Post Ipo Equity |
| PHARMAKON ADVISORS LP | Post Ipo Debt |
Search for jobs
Coherus BioSciences highest paying jobs
Zippia gives an in-depth look into the details of Coherus BioSciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Coherus BioSciences. The employee data is based on information from people who have self-reported their past or current employments at Coherus BioSciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Coherus BioSciences. The data presented on this page does not represent the view of Coherus BioSciences and its employees or that of Zippia.
Coherus BioSciences may also be known as or be related to COHERUS BIOSCIENCES INC., Coherus BioSciences, Coherus BioSciences Inc, Coherus BioSciences, Inc., Coherus Biosciences and Coherus Biosciences Inc.